2. Academic Validation
  3. Shuangshen ningxin formula attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial function

Shuangshen ningxin formula attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial function

  • J Ethnopharmacol. 2024 Jan 7:117690. doi: 10.1016/j.jep.2023.117690.
ZiXin Liu 1,  Xiao Han 2,  Yue You 3,  GaoJie Xin 4,  LingMei Li 5,  JiaMing Gao 6,  HongXu Meng 7,  Ce Cao 8,  JianXun Liu 9,  YeHao Zhang 10,  Lei Li 11,  JianHua Fu 12
Affiliations

Affiliations

  • 1 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: 641758689@qq.com.
  • 2 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: hxfresh@sina.com.
  • 3 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: youyue90996@163.com.
  • 4 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: 2399310579@qq.com.
  • 5 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: 1136819527@qq.com.
  • 6 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: gaojmamazing@163.com.
  • 7 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: amfd003@163.com.
  • 8 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: caoce1@foxmail.com.
  • 9 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: liujx0324@sina.com.
  • 10 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: zyh322@163.com.
  • 11 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: lilei0502@126.com.
  • 12 Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing 100091, PR China. Electronic address: jianhuaffcn@263.net.
PMID: 38195019 DOI: 10.1016/j.jep.2023.117690
Abstract

Ethnopharmacological relevance: Shuangshen Ningxin Formula (SSNX) is a traditional Chinese medicine formula used to treat myocardial ischemia-reperfusion injury (MIRI). A randomized controlled trial previously showed that SSNX reduced cardiovascular events, and experiments have also verified that SSNX attenuated ischemia-reperfusion (I/R) injury. However, the mechanism of SSNX in the treatment of microvascular I/R injury is still unclear.

Aim of the study: To determine whether SSNX protects the microvasculature by regulating I/R induction in rats and whether this effect depends on the regulation of NR4A1/Mff/Drp1 pathway.

Methods: The anterior descending coronary artery was ligated to establish a rat MIRI model with 45 min of ischemia and 24 h of reperfusion. The rats were subjected to a 7-day pretreatment with SSNX and nicorandil, after which their cardiac function and microvascular functional morphology were evaluated through diverse methods, including hematoxylin and eosin (HE) staining, wheat germ agglutinin (WGA) staining, and transmission electron microscopy. Cell Apoptosis was assessed using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Additionally, serum levels of ET-1 and eNOS were determined through an enzyme-linked immunosorbent assay (ELISA). The expression levels of NR4A1, Mff, and proteins related to mitochondrial fission were examined by Western blot (WB). Cardiac microcirculation endothelial cells (CMECs) were cultured and the oxygen-glucose deprivation/reoxygenation (OGD/R) model was duplicated. Following treatment with SSNX and DIM-C-pPhOH, an NR4A1 inhibitor, cell viability was assessed. Fluorescence was used to evaluate mitochondrial membrane potential (MMP) and mitochondrial permeability transition pore (MPTP) opening. Moreover, vascular endothelial function was evaluated through transendothelial electrical resistance (TEER), Transwell assays and tube formation assays.

Results: The results showed that SSNX reduced the infarction area and no-flow area, improved cardiac function, mitigated pathological alterations, increased endothelial nitric oxide synthase expression, protected endothelial function, and attenuated microvascular damage after I/R injury. I/R triggered mitochondrial fission and apoptotic signaling in CMECs, while SSNX restored mitochondrial fission to normal levels and inhibited mitochondrial Apoptosis. A study using CMECs revealed that SSNX protected endothelial function after OGD/R, attenuating the increase in NR4A1/Mff/Drp1 protein and inactivating VDAC1, HK2, cytochrome c (cyt-c) and caspase-9. Research also shows that SSNX can affect CMEC cell migration and angiogenesis, reduce mitochondrial membrane potential damage, and inhibit membrane opening. Moreover, DIM-C-pPhOH, an NR4A1 inhibitor, partially imitated the effect of SSNX.

Conclusion: SSNX has a protective effect on the cardiac microvasculature by inhibiting the NR4A1/Mff/Drp1 pathway both in vivo and in vitro.

Keywords

Cardiac microvascular I/R injury; Mitochondrial function; NR4A1/mff/Drp1pathway; ShuangShenNingXin formula.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z